Dopamine Receptor

Dopamine receptors are GPCRs through which dopamine regulates motor function, motivation, drive, cognition, and peripheral physiology^[1][2]. Mechanistically, dopamine receptor signaling is organized into D₁-like receptors (D₁, D₅) and D₂-like receptors (D_2S, D_2L, D₃, D₄), enabling subtype-specific control of cAMP-mediated and non-canonical signaling^[1][3]. In disease-oriented research, dopamine-glutamate-NMDA interactions and dopamine receptor ligands provide experimental frameworks for schizophrenia, Parkinson’s disease, depression, bipolar disorder, and addiction models^[1][3]. Compared with related isoforms, D₁-D₂ receptor heteromers form a pharmacologically distinct signaling complex coupled to G_q/11, requiring agonist binding to both receptors for G protein activation and intracellular calcium release^[4]. This calcium pathway links D₁-D₂ receptor heteromer activation to CaMKIIα, BDNF production, and neuronal growth in striatal models^[5]. Compared with D₁, D₅ shows high agonist affinity and constitutive activity shaped by carboxyl-terminal tail sequence and intracellular loop determinants^[6][7]. Therefore, subtype-selective agonists, antagonists, partial agonists, and heteromer-directed ligands remain practical tools for dissecting dopamine receptor pharmacology, signaling bias, and disease-relevant neurocircuit mechanisms^[1][3][4].